<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The bcl-2 oncogene blocks programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> (<z:mpath ids='MPATH_3'>apoptosis</z:mpath>) </plain></SENT>
<SENT sid="1" pm="."><plain>Epstein-Barr virus (EBV) can immortalize B lymphocytes into continuously growing lymphoblastoid cell lines (LCL) by the coordinate expression of at least 9 latent genes (EBV nuclear antigen [EBNA] 1-6, latent membrane protein [LMP], and terminal proteins [TP] 1 and 2) </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed transcription and expression of bcl-2 and latent EBV genes in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines with a germinal center phenotype (group I) as well as activated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines (group III) and LCLs </plain></SENT>
<SENT sid="3" pm="."><plain>We found high expression of bcl-2 as well as the full spectrum of latent EBV genes in LCLs and activated group III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>Group I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells expressed little or no bcl-2, EBNA-2, and LMP </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0038826" disease_type="Disease or Syndrome" abbrv="">Superinfection</z:e> with nondefective EBV or an EBNA-2-defective virus as well as transfection with EBNA-2- or LMP-carrying vectors into the EBV-negative cell lines RAMOS, DG75, U698, or BJAB induced upregulation of bcl-2 expression </plain></SENT>
<SENT sid="6" pm="."><plain>The strongest effect on bcl-2 was obtained by transfection with LMP, or <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with the nondefective virus </plain></SENT>
<SENT sid="7" pm="."><plain>No change of bcl-2 expression was observed with EBNA-1 </plain></SENT>
<SENT sid="8" pm="."><plain>Our data indicate that the immortalization capacity of EBV and the growth advantage of EBV-positive compared with EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells in vitro may predominantly be mediated via induction of bcl-2 and the main effectors are EBNA-2 and LMP </plain></SENT>
</text></document>